AbbVie Inc

AbbVie’s Q3 miss yet raised guidance, dividend hike, and drug‑price talks show how a pharma giant balances earnings, returns and regulation.

AbbVie’s recent analyst upgrades spotlight its strong pipeline, solid cash flow and disciplined capital allocation—making the biotech stock a compelling, risk‑adjusted growth opportunity.

AbbVie refines its chronic inflammation partnership with OSE Immunotherapeutics, shifting Phase‑1 duties and boosting ABBV‑230’s development while retaining long‑term equity and regulatory control.

AbbVie boosts Skyrizi advertising, outpacing J&J’s Tremfya, and sponsors a high‑profile ESMO Asia oncology symposium—showing strategic focus on psoriasis, ovarian cancer ADCs, and expanding dermatologic research.

AbbVie’s latest migraine and immunology data reveal how the company plans to win EU payers, beat CGRP rivals, and protect revenue before Humira’s patent ends.

AbbVie’s new atogepant data and protein‑degradation pipeline highlight its bid to dominate migraine and unlock untapped markets, while it navigates generic threats to Restasis and expands its precision‑medicine portfolio.

AbbVie’s Skyrizi gets Canada’s public drug plan approval, boosting ulcerative colitis access and revenue prospects for the specialty pharma leader.

AbbVie’s rising earnings outlook, robust oncology pipeline and strategic ADC focus highlight its growth in targeted cancer therapies and long‑term investor confidence.

AbbVie’s first FDA‑approved bispecific antibody, EPKINLY + R2, opens a new front for relapsed follicular lymphoma—offering clinical gains, market edge and $300‑$500 m potential upside.

AbbVie’s musculoskeletal oncology focus, strong cash flow and strategic M&A plans are driving bullish analyst sentiment and higher price targets despite looming patent cliffs.